全文3195字,阅读约需10分钟,帮我划重点划重点01GLP-1减肥药在全球持续火爆,头部产品司美格鲁肽和替尔泊肽2024年前三季度销售业绩亮眼。02由于参与者持续增加和新建产能陆续建成,GLP-1产业竞争格局愈发激烈。03然而,国产GLP-1创新药与仿制药或将在2026年前后陆续进入大规模商业化阶段。04另一方面,全球减肥市场对于GLP-1药物的需求是否如设想般稳固仍存不确定性。05多肽原料药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.